2025 Annual Meeting | Industry Therapeutic Update from Eisai Inc.: Driving Change for Anti-amyloid Therapy Implementation: Overcoming Challenges Across Practice Settings

��ɫ��

2025 Annual Meeting | Industry Therapeutic Update from Eisai Inc.: Driving Change for Anti-amyloid Therapy Implementation: Overcoming Challenges Across Practice Settings

Date Monday 04/07/25

Time 11:45 AM - 12:45 PM PDT Add To Calendar

Location San Diego Convention Center | 6CF

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Topic(s) General Neurology, Aging, Dementia, and Behavioral Neurology

Learning Objectives This session aims to provide practical strategies to help overcome challenges in implementation of monoclonal antibody (mAb) therapies for treatment of Alzheimer’s disease (AD) across diverse neurology practice settings. Three practicing neurologists with experience treating patients with anti-amyloid mAbs will share recommendations from their clinical experience as well as expert-developed resources, including roadmaps for use of mAbs throughout the AD diagnosis and treatment process. First, we will provide an overview of the AD Patient Pathway, which is a guide to prepare integrated delivery networks for implementation of mAb therapies, including best practices and operational strategies for establishing anti-amyloid treatment programs. Then, we will review consensus recommendations from clinicians and administrators who have successfully implemented anti-amyloid mAbs within private practice settings. Finally, we will discuss some practical considerations for accessing and using expert-developed resources, so that attendees can feel more confident applying these strategies to administer anti-amyloid mAbs for treatment of AD across care settings. This session will emphasize flexibility for treatment implementation strategies and the role of expert guidance when establishing treatment pathways for therapies.
This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2025 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Program Materials

Event Timeline
11:45 AM - 12:45 PM PDT	Speaker	Industry Therapeutic Update from Eisai Inc.: Driving Change for Anti-amyloid Therapy Implementation: Overcoming Challenges Across Practice Settings

��ɫ����

��ɫ����

��ɫ��

��ɫ��